Print Page  E-mail Page  RSS  E-mail Alerts  Tearsheet 

Investor Home

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, products.

AAA is a European leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. These radiopharmaceuticals are mainly used for diagnosis in clinical oncology, cardiology and neurology.

...
more >
Latest Newsmore >
07/27/17
Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera®) to FDA
Conference Call Today at 5:00 p.m. ET SAINT-GENIS-POUILLY, France, July 27, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the resubmission of the New Drug Application (NDA) for investigational drug lutetium Lu 177 dotatate* (Lutathera®) to the US Food and Drug Administration (FDA) was completed. AAA resubmitted the NDA following receipt of a complete r... 
07/21/17
Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors
SAINT-GENIS-POUILLY, France, July 21, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the marketing authorization of lutetium (177Lu) oxodotreotide* (Lutathera®) for the treatment of unresectable or metastatic, progressi... 
05/31/17
Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017
On Track to Resubmit NDA for lutetium Lu 177 dotatate (Lutathera®) to FDA in Mid-2017 NETSPOT® Unit Sales per Month Jump 140% During First Quarter First Quarter 2017 Highlights: Advanced preparations for resubmission of lutetium Lu 177 dotatate (Lutathera®) New Drug Application to FDA Results of Phase 3 NETTER-1 study of investigational drug lutetium Lu 177 dotatate (Lutathera®) published in The New England Journal of Medicine Enhanced supply chain for lutetium 177-labeled product... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources